Dataset from A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)

The study objective of Period 1 (Day 1 to Week 24) is to compare the safety and efficacy of
upadacitinib 30 mg once daily (QD) and 15 mg QD versus placebo for the treatment of signs and
symptoms of participants with moderately to severely active rheumatoid arthritis (RA) who are
on a stable dose of csDMARDs and had an inadequate response to or intolerance to at least 1
bDMARD.

The study objective of Period 2 (Week 24 to Week 260) is to evaluate the long-term safety,
tolerability, and efficacy of upadacitinib 15 mg QD and 30 mg QD in participants with RA who
completed Period 1.